Publications by authors named "F Girardin"
Highly sensitive ultra-high-performance liquid chromatography coupled with tandem mass spectrometry method for the multiplex analysis of levosimendan and its metabolites OR-1855 and OR-1896 in human plasma.
J Pharm Biomed Anal
December 2024
Levosimendan is a positive inotrope and vasodilator used in patients with acute and chronic decompensated heart failure. It is metabolized into OR-1855 (inactive metabolite), which is further acetylated into OR-1896 (active metabolite having a prolonged half-life, hence a sustained effect). Levosimendan represents a valuable alternative to traditional inotropes with broad clinical applications in critically ill patients with cardiogenic shock, advanced heart failure and post-cardiac surgery.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how long-acting rilpivirine functions in real-life clinical settings, addressing gaps left by clinical trials on its pharmacokinetics in people with HIV.
- Researchers analyzed data from 238 patients to establish concentration curves and identify factors influencing drug exposure, finding differences in absorption rates between genders but minimal clinical impact.
- The findings suggest that around 50% of rilpivirine concentrations meet the optimal therapeutic threshold, indicating potential variability in treatment effectiveness among patients.
Background: Despite major advances in cancer treatment in the past years, there is a need to optimize chemotherapeutic drug dosing strategies to reduce toxicities, suboptimal responses, and the risk of relapse. Most cancer drugs have a narrow therapeutic index with substantial pharmacokinetics variability. Yet, current dosing approaches do not fully account for the complex pathophysiological characteristics of the patients.
View Article and Find Full Text PDFBackground: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is unclear.
Methods: We conducted a cohort study that included kidney-transplant recipients from more than 30 transplantation centers in Europe and North America who had undergone allograft biopsy between 2004 and 2023.
Article Synopsis
- Drug dosing guidelines are based on average responses in the population, but individual differences can lead to ineffective treatment or adverse reactions due to genetic factors affecting drug metabolism.
- A study genotyped 1533 Swiss patients to assess the prevalence of actionable genetic variants in relation to drug prescriptions, finding that 97.3% of participants had at least one variant.
- The research indicates that 31% of patients received medications that could lead to adverse reactions due to these genetic variants, suggesting that personalized medicine could improve healthcare outcomes.